CellaVision AB (0MR5)
London Exchange · UK · prices in SEK · close of 21 Oct 2026
Key indicators
| Last close | SEK 164.90 |
|---|---|
| 52-week range | 118.58 – 184.52 |
| Return, 1 month / 3 months | −0.4% / +18.1% |
| Return, 1 year / 3 years | −10.3% / +28.0% |
| Trend | Uptrend |
| RSI (14) | 48 |
| Volatility (1 year) | 41.4% |
| Worst drawdown (1 year) | -35.7% |
| Average daily value traded | 0.11M SEK |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
CellaVision is a Swedish medical technology company based in Lund that develops automated digital microscopy systems for analysing blood and other body fluids. Its instruments and software capture images of blood smears and classify and count white blood cells, helping laboratory professionals examine samples. Customers are hospital and clinical laboratories that need efficient, standardised cell analysis. The company also supplies related reagents, software and support services to these laboratory customers.
CellaVision AB trades under the code 0MR5 on the London Exchange in UK, with its price quoted in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
CellaVision AB (0MR5) trades on the London Exchange in UK. It last closed at SEK 164.90 on 21 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 1,870 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.3% and over the last three months it rose 18.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 75 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 12.2% | ||
| From 52-week high | -10.6% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 18.1% | ||
| 6-month return | 9.7% | ||
| 12-month return, skipping the last month | -10.0% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.7% | ||
| Liquidity | 31 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.11M SEK | ||
| Zero-volume days | 30.0% | ||
| Income | 49 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −0.4% |
| 3 months | +18.1% |
| 6 months | +9.7% |
| 1 year | −10.3% |
| 3 years | +28.0% |
| 5 years | −57.8% |
Signals
| 50-day / 200-day average | 164.28 / 147.03 |
|---|---|
| Golden / death cross (60 days) | Golden, 42 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.85 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Apr 2026 | SEK 2.7500 |
| 7 May 2025 | SEK 2.5000 |
| 3 May 2024 | SEK 2.2500 |
| 5 May 2023 | SEK 2.2500 |
| 12 May 2022 | SEK 2.0000 |
| 30 Apr 2021 | SEK 0.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.